Drugs in Dev. Oncology
Preclinical
Poland 
Lead Product(s) : OAT-3912
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Ocean Biomedical
Deal Size : $32.6 million
Deal Type : Licensing Agreement
Ocean Biomedical Pens $32M Pact for Polish YKL-40 Inhibitors
Details : Under the agreement, Ocean Biomedical gains the exclusive rights to further research, develop, manufacture and commercialize Molecure’s OAT-3912 and other selective YKL-40 inhibitors worldwide.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $0.6 million
October 15, 2024
Lead Product(s) : OAT-3912
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Ocean Biomedical
Deal Size : $32.6 million
Deal Type : Licensing Agreement
Lead Product(s) : CPT-6281
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CPT-6281 as drug candidate for the CT-01 project, which will initially focus on the clinical development of the asset as a TPD treatment against hepatocellular carcinoma (HCC).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 10, 2022
Lead Product(s) : CPT-6281
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CT-01
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Compelling in-vitro and in-vivo preclinical data demonstrate that CT-01 candidate compounds induce degradation of Eukaryotic peptide chain release factor GTP-binding subunit, and another undisclosed neo-substrate with essential function in tumorigenesis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 11, 2022
Lead Product(s) : CT-01
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CT-01
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Strong and comparable efficacy was demonstrated with CT-01 candidate, also confirming the potent antitumor activity in a liver cancer mouse xenograft model and no treatment-related toxicity was observed.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 13, 2022
Lead Product(s) : CT-01
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Berubicin
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
WPD Pharma to Conduct Clinical Trials in Pediatric Brain Tumors
Details : The Company, in collaboration with CNS, is planning to conduct the upcoming Phase I clinical trial at Children's Memorial Health Institute
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 12, 2020
Lead Product(s) : Berubicin
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
